Oxford will study top-selling prescription drug for potential Covid-19 treatment
September 30 2020 12:30 PM
Oxford University
Oxford University

Reuters

Britain's Oxford University said today it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for Covid-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.

The AVID-CC trial will test the anti-tumour necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enrol up to 750 patients from community care settings throughout the UK.




There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*
MORE NEWS

HAPPENING IN DOHAMore